TY - JOUR
T1 - The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn’s Disease
T2 - A Cross-Sectional Study
AU - Ciccocioppo, Rachele
AU - Imbesi, Venerina
AU - Betti, Elena
AU - Boccaccio, Vincenzo
AU - Kruzliak, Peter
AU - Gallia, Alessandra
AU - Cangemi, Giuseppina Cristina
AU - Maffe, Gabriella Carnevale
AU - Vanoli, Alessandro
AU - Merante, Serena
AU - De Amici, Mara
AU - Falcone, Colomba
AU - Klersy, Catherine
AU - Corazza, Gino Roberto
PY - 2015/8/23
Y1 - 2015/8/23
N2 - Background: RAGE is a transmembrane receptor expressed on immune and endothelial cells, whose binding with its ligands, the S100 calgranulins, leads to chronic inflammation. Conversely, its soluble form (sRAGE) plays a protective role by acting as a decoy. We carried out a cross-sectional analysis of the sRAGE and S100A12 serum levels in patients with Crohn’s disease (CD) and ulcerative colitis (UC) and searched for a correlation with clinical and biological markers of activity. Methods: We enrolled 60 CD, 67 UC patients, and 66 controls (all adults). Disease activity was scored through the clinical, endoscopic, and histologic indexes of severity, whilst disease location and behaviour were assessed according to the Montreal classification. In all cases, the levels of serum sRAGE, S100A12, C-reactive protein, and faecal calprotectin were measured. Results: sRAGE levels were significantly lower in UC, both active and inactive, than in controls and CD (817.35, range 437.3–1449; 1211, range 843.7–1618; 1207.5, range 743.15–1875.75; P
AB - Background: RAGE is a transmembrane receptor expressed on immune and endothelial cells, whose binding with its ligands, the S100 calgranulins, leads to chronic inflammation. Conversely, its soluble form (sRAGE) plays a protective role by acting as a decoy. We carried out a cross-sectional analysis of the sRAGE and S100A12 serum levels in patients with Crohn’s disease (CD) and ulcerative colitis (UC) and searched for a correlation with clinical and biological markers of activity. Methods: We enrolled 60 CD, 67 UC patients, and 66 controls (all adults). Disease activity was scored through the clinical, endoscopic, and histologic indexes of severity, whilst disease location and behaviour were assessed according to the Montreal classification. In all cases, the levels of serum sRAGE, S100A12, C-reactive protein, and faecal calprotectin were measured. Results: sRAGE levels were significantly lower in UC, both active and inactive, than in controls and CD (817.35, range 437.3–1449; 1211, range 843.7–1618; 1207.5, range 743.15–1875.75; P
KW - Biomarker
KW - Crohn’s disease
KW - Disease activity
KW - Receptor for the advanced glycation end products
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84937526243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937526243&partnerID=8YFLogxK
U2 - 10.1007/s10620-015-3619-7
DO - 10.1007/s10620-015-3619-7
M3 - Article
C2 - 25757448
AN - SCOPUS:84937526243
VL - 60
SP - 2327
EP - 2337
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 8
ER -